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Abstract
NF-kB plays a variety of roles in oncogenesis and immunity that
may be beneficial for therapeutic targeting, but strategies to
selectively inhibit NF-kB to exert antitumor activity have been
elusive. Here, we describe IT-901, a bioactive naphthalenethio-
barbiturate derivative that potently inhibits the NF-kB subunit
c-Rel. IT-901 suppressed graft-versus-host diseasewhile preserving
graft-versus-lymphoma activity during allogeneic transplantation.
Further preclinical assessment of IT-901 for the treatment of
human B-cell lymphoma revealed antitumor properties in vitro
and in vivo without restriction to NF-kB–dependent lymphoma.
This nondiscriminatory, antilymphoma effect was attributed to
modulation of the redox homeostasis in lymphoma cells resulting
in oxidative stress. Moreover, NF-kB inhibition by IT-901 resulted
in reduced stimulation of the oxidative stress response gene heme
oxygenase-1, and we demonstrated that NF-kB inhibition exacer-
bated oxidative stress induction to inhibit growth of lymphoma
cells. Notably, IT-901 did not elicit increased levels of reactive
oxygen species in normal leukocytes, illustrating its cancer selec-
tive properties. Taken together, our results provide mechanistic
insight and preclinical proof of concept for IT-901 as a novel
therapeutic agent to treat human lymphoid tumors and amelio-
rate graft-versus-host disease. Cancer Res; 76(2); 377–89.2016 AACR.
Introduction
Amongst its many functions, NF-kB plays important roles in
immunity (1–6) and oncogenesis (1, 7), indicating that thera-
peutic targeting of this pathway could be beneficial in a variety of
clinical settings; however, an NF-kB–specific inhibitor does not
exist in clinical practice to date. One approach toward develop-
ment of such a compound is small-molecule–mediated direct
inhibition of one or several members of the NF-kB family of
transcription factors, a network that comprises five structurally
related proteins including p50 (NF-kB1), p52 (NF-kB2), p65
(RelA), RelB, and c-Rel (8).
After screening of a library of 15,000 small molecules with a
biochemical assay measuring inhibition of c-Rel interaction
with its high-affinity DNA-binding site, we identified two
scaffolds with inhibitory activity for the NF-kB family of
transcription factors and particularly high specificity for the
transcription factor c-Rel. These scaffolds, thiohydantoin and
napthalenethiobarbitutate, act as direct NF-kB inhibitors by
preventing DNA binding of the c-Rel protein. We previously
reported that in vitro treatment of T cells with the thiohydan-
toin IT-603 induces c-Rel deficiency, resulting in suppression
of T-cell alloactivation without compromising T-cell activation
triggered by recognition of tumor-associated or viral antigens
(9). Here, we demonstrate significant in vivo efficacy of the
naphthalenethiobarbiturate IT-901 in mouse models of graft-
versus-host disease (GVHD) and graft-versus-lymphoma
(GVL), as well as a xenograft model of human B-cell lympho-
ma, revealing that IT-901 treatment results not only in
suppression of GVHD while retaining GVL activity, but it also
mediates promising antilymphoma effects. We characterize
pharmacokinetic (PK) and toxicology profiles as well as the
mechanism of action of IT-901–mediated antilymphoma
activity in human diffuse large B-cell lymphoma (DLBCL)
cells, thereby laying the groundwork for the development of
a new drug combining unique immunomodulatory and anti-
neoplastic properties.
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Materials and Methods
Mice and bone marrow transplantation
We obtained female C57BL/6 (B6, H-2b), BALB/c (H-2d) from
the Jackson Laboratory. Male NOD/scid/IL2Rg(null; NSG) mice
were purchased from the Jackson Laboratory. BALB/C-Tg(NFkB-
RE-luc)-Xen mice were obtained from Taconic. B6 mice carrying
the c-Rel gene null mutation (c-Rel/) were originally generated
by inserting the neomycin cassette into the fifth exon of the c-Rel
gene (3). c-Rel/ B6 mice were maintained at Memorial Sloan
Kettering Cancer Center (New York, NY) in accordance with
Institutional Animal Care and Use Committee Standards. Mice
used for experiments were 6 to 9 weeks old. Mouse HSCT
experiments were performed as previously described (10), with
850 cGy split-dosed lethal irradiation of BALB/c recipients trans-
planted with bone marrow (5 106), T cell depleted (TCD) with
anti-Thy-1.2 and low-TOX-M rabbit complement (Cedarlane
Laboratories). Mouse T cells were prepared by harvesting donor
splenocytes and enriching T cells by Miltenyi MACS purification
of CD5 (routinely >90% purity). In A20 lymphoma experiments,
animals received tumor cells intravenously in a separate injection
on day 0.
Small-molecule c-Rel inhibitor compounds
Our team previously identified thiohydantoin and naphthale-
nethiobarbiturate derivatives as conformation-disrupting direct
c-Rel inhibitors (9, 11, 12). c-Rel inhibitory activity of these small-
molecule compounds was confirmed by fluorescence polariza-
tion (FP) as well as electrophoretic mobility shift assay (EMSA)
utilizing the DNA-binding property of the c-Rel protein. NF-kB
DNA-binding ELISA (TransAMNFkB Family kit fromActiveMotif
North America, see the manufacturer's protocol for more details)
was also used to evaluate the activation of c-Rel. To obtain an
estimate of the IC50, a constant amount of 32p-labeled-kB probe
(1 nmol/L, CD28RE) and c-Rel protein (5 nmol/L) was incubated
with serial dilutions of IT-901 (50 mmol/L to 100 nmol/L) for 20
minutes in a 20-mL reaction at room temperature. The reactions
were then resolved on native polyacrylamide gel following the
standard protocol described previously (13). The c-Rel inhibitors
IT-603 and IT-901 were provided by ImmuneTarget Inc.
Assessment of GVHD and GVT; in vivo BLI
Mice were monitored daily for survival and weekly for GVHD
clinical scores (14). In GVT experiments, we determined the
bioluminescent signal intensity (BLI) of tumor-bearing mice
twice weekly as described previously (15). We superimposed
pseudocolor images showing the whole-body distribution of
bioluminescent signal intensity on grayscale photographs and
determined total flux (photons/s) for individual mice. We deter-
mined the cause of death (tumor vs. GVHD) by necropsy and
histopathology as previously described (16).
Cell lines and primary cells
A20, a B-cell lymphoma cell line of BALB/c origin, was kindly
provided by A. Houghton (Memorial Sloan Kettering Cancer
Center). We retrovirally transduced A20 to express a triple fusion
protein consisting of herpes simplex virus thymidine kinase,
enhancedGFP, andfirefly luciferase (TGL) as described previously
(17). The human DLBCL-derived cell lines SU-DHL4, OCI-Ly19,
U2932 were obtained from the German Collection of Microor-
ganisms and Cell Cultures, Department of Human and Animal
Cell Cultures (Braunschweig, Germany); SU-DHL8 cells, were
obtained from ATCC. The HBL1 and TMD8 cells were kindly
provided by Dr. R.E. Davis (Houston, TX), and authenticated
before using them by the MD Anderson Characterized Cell Lines
Core Facility. Cell lines were cultured in RPMI-1640 medium
supplemented with 10% to 20% heat-inactivated FBS (GIBCO
BRL), 1% L-glutamine, and penicillin-streptomycin in a humid
environment of 5%CO2 at 37C. AnNF-kB/Jurkat/GFP transcrip-
tional reporter cell line (18) was purchased from System Bio-
sciences. Cells were stimulated with human TNFa (10 ng/mL)
and incubated in the presence of IT-603, IT-901, or empty vehicle
for 20 hours. NF-kB activity (GFP fluorescence intensity) and
viability (based on DAPI) were analyzed by flow cytometry.
Combined data from three independent experiments are pre-
sented. Human CD19þ peripheral blood mononuclear cells
(PBMC) were purchased from United States Biological. Human
primary B-cell lymphoma and T-cell lymphoma cells were
obtained from the Hematology/Oncology Tissue Bank at Memo-
rial Sloan Kettering Cancer Center. Sample and patient data
collection were approved by the Human Biospecimen Utilization
Committee and the Institutional Review Board/Privacy Board-B
of Memorial Sloan Kettering Cancer Center.
Human EBV-transformed B lymphoblastoid cells were gener-
ated from PBMC of a healthy donor. Human EBV-specific T cells
were generated from PBMC of the same donor by repeated in vitro
stimulations with an autologous EBV-transformed B cells.
Serum cytokines analyses
Blood was collected intomicrocentrifuge tubes, allowed to clot
and centrifuged, and the supernatant was collected. Multiplex
ELISAwas conducted permanufacturer's instructions (Millipore).
Results were acquired with a Luminex 200 instrument and ana-
lyzed with xPONENT software (Luminex Corporation).
Antibodies and flow cytometry
All antibodies other than the anti–c-Rel, anti-p50, anti-p52
antibodies (Santa Cruz Biotechnology), and the anti-CD44, anti-
p65 antibodies (Biolegend) were obtained from BD Biosciences –
Pharmingen. For cell analysis of surface markers, cells were
stained for 20 minutes at 4C in PBS with 0.5% BSA (PBS/BSA)
after Fc block, washed, and resuspended inDAPI in PBS/BSA. Cell
surface staining was followed by intracellular staining with the
eBioscience kit as per the manufacturer's instructions. Dead cells
were excluded with LIVE/DEAD Fixable Dead Cell Stain kit
(Invitrogen). Intranuclear c-Rel staining was performed as previ-
ously described (9). All flow cytometry was performed on an LSR
II (BDBiosciences) and analyzedwith FlowJo (TreeStar Software).
Human anti-adalimumab was purchased from AbD Serotec (Bio-
Rad Laboratories, Inc).
MTS assay
Relative cell growth was measured by the CellTiter 96 Aqueous
Non-Radioactive Cell Proliferation Assay (Promega) as per
the manufacturer's instructions. Briefly, tetrazolium compound
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] was added to
the culture media and the conversion of MTS into formazon
was measured by the amount of 490 nm absorbance. The
number of viable cells correlates with absorbance at 490 nm
(see the manufacturer's protocol for more details).
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qPCR
Reverse transcription-PCR was performed with iScript
Advanced cDNA Synthesis Kit for RT-qPCR (BIO-RAD). For
real-time PCR, NF-kB signaling pathway Plus PrimePCR Pathway
Plate was used per manufacturer's instructions (BIO-RAD). PCR
was done on CFX96 Touch Real-Time PCR (Bio-Rad) with Uni-
versal SYBR Green Supermix (BIO-RAD). Relative amount of
HMOX1 was calculated by the comparative DC(t) method utiliz-
ing CFX Manager Software (BIO-RAD).
Heme oxygenase-1 ELISA
In order to measure heme oxygenase-1 (HMOX1) protein level
in IT-901–treated Ly19 human DLBCL, Ly19 cells were lysed with
extraction reagent included in the HO-1 Human ELISA Kit
(Abcam). Analysis was performed per manufacturer's instruc-
tions. Optical density (OD) was determined, using a microplate
autoreader (Bio-Tek Optiplex 755Microplate Reader) at 450 nm.
HMOX1 protein concentration of the samples was determined
based on a specific HMOX1 standard curve.
Mouse IL2 ELISA
IL2 production by activated T cells was measured with the
Mouse IL-2 ELISA Kit purchased from Sigma-Aldrich. Wild-type
C57BL/6 mouse splenocytes were treated with different concen-
trations of IT-901 or empty vehicle for one hour and stimulated in
vitro with anti-CD3/CD28 for 5 hours. Cell culture supernatants
were analyzed for IL2 as per the manufacturer's instructions.
Inducible nitric oxide synthase ELISA
An ELISA-based assay was performed tomeasure total inducible
nitric oxide synthase (iNOS) in IT-901–treated human DLBCL
including Ly19, SU-DHL8, and TMD8 cells. Cells were treated in
vitro with IT-901 (4 mmol/L) or control solution for 24 hours in a
96-well microplate. After fixation of cells in the wells, iNOS levels
were determinedusingHumanTotal iNOSCell-BasedELISA (R&D
Systems) as per the manufacturer's instructions.
Detection of reactive oxygen species and treatment with
N-Acetyl-L-cysteine
B-cell lymphomacellswere treated in vitrowith IT-901 (4mmol/L)
or control solution for different time periods to induce reactive
oxygen species (ROS) generation. ROS levels were analyzed by
utilizing the Image-iT LIVE Green Reactive Oxygen Species Detec-
tion Kit (Molecular Probes, Invitrogen) as per the manufacturer's
instructions. ROS levels were analyzed by quantifying a fluoro-
genic marker (carboxy-H2DCFDA) using flow cytometry (LSR II,
BDBiosciences).N-Acetyl-L-cysteinewas purchased fromSIGMA-
ALDRICH. Formicroscopic detection of ROS, IT-901–treated cells
were stained with carboxy-H2DCFDA, MitoTracker Deep Red FM
(Life Technologies), and Hoechst 33342 (Life Technologies),
followed by laser scanning confocal microscopy on a Leica SP5
confocal microscope.
Detection of reactive oxygen and reactive nitrogen species
Analyses of superoxide, hydrogen peroxide, and reactive nitro-
gen levels were performed with IT-901–treated human DLBCL
including Ly19, SU-DHL8, and TMD8 cells. Cells were treated in
vitro with IT-901 (4 mmol/L) or control solution for 24 hours and
the levels of superoxide, hydrogen peroxide and reactive nitrogen
were determined by MitoSOX Red Mitochondrial Superoxide
Indicator, Premo Cellular Hydrogen Peroxide Sensor, and DAF-
FM Diacetate, respectively, as per the manufacturer's instructions
(Life Technologies). The fluorescence intensities of cells after
treatment were detected by flow cytometry (LSR II, BD
Biosciences).
Glutathione assay
Ly19, SUDH8, and TMD8 cells were treated with IT-901 at 4
mmol/L or control vehicle for 24 hours and cells were analyzed for
total and oxidized glutathione by the HT Glutathione Assay Kit
(Trevigen Inc.) as per the manufacturer's protocol. Reduced GSH
was calculated by subtracting oxidized GSSG from total
glutathione.
Mitochondrial respiration assay
Real-time measurement of oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR) in Ly19 cells were
conducted in a XF96 extracellular flux analyzer (Seahorse Bio-
science). Briefly, Ly19 cells treated either with IT-901 at 4 mmol/L
or control vehicle 3 to 24 hours were washed with RPMI-1640
supplemented with 10% FBS and L-glutamine, resuspended
in mitochondria stress medium (DMEM supplemented with
10 mmol/L glucose, 1 mmol/L pyruvate, 2 mmol/L glutamine,
pH 7.35) and transferred to a XF96 cell culture microplates
(Seahorse Bioscience) pretreated with Cell-Tak (BD Biosciences)
at a density of 200,000 cells per well. After incubation at 37C in
the absence of CO2 for 1 hour in a Prep Station incubator
Station, real-time measurements of OCR were collected at inter-
vals of 4 minutes as a parameter of mitochondrial respiration.
The standard assay was carried out and used the compounds
stock provided in the XF Cell Mito Stress Test Kit. After optimi-
zation of oligomycin and FCCP working concentration, the
mitochondrial stress assay was conducted following the manu-
facturer's instructions.
c-Rel knockdown with shRNA
An optimized miRNA backbone (miR-E) for effective c-Rel
knockdown was designed according to a previous report (19).
We designed 12 different sequences for efficient c-Rel targeting by
shRNAandutilized two (#2131 and#2205) in our experiments to
analyze the HMOX1 level in c-Rel knocked-down Ly19 lympho-
ma cells. 97-mir sequences of the two shRNAs are TG-
CTGTTGACAGTGAGCGACAGCATTTTGTATTTGTCTAATAGTG-
AAGCCACAGATGTATTAGACAAATACAAAATGCTGCTGCCTAC-
TGCCTCGGA (#2131) and TGCTGTTGACAGTGAGCGCAAT-
ACTGTATTTGAGAATATATAGTGAAGCCACAGATGTATATATTC-
TCAAATACAGTATTATGCCTACTGCCTCGGA (#2205). Ly19
cells were resuspended in lentivirus-containing supernatant in
the presence of polybrene (4 ng/mmL) and incubated at 37C in a
CO2 incubator for 24 hours. Transduced cell populations were
selected 7 days after infection using 0.5 ng/mL puromycin (Sigma-
Aldrich).
Analysis of c-Rel gene expression in human cells
c-Rel expression data from human primary cells and cell lines
were obtained from several publically available databases. Micro-
array data normalized by RMA and RNA sequencing data nor-
malized by RPKMwere obtained from The Broad Institute of MIT
and Harvard (20, 21).
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Pharmacokinetics
Plasma samples were analyzed at 30 minutes, 1, 2, 4, 6, and 16
hours after intraperitoneal, subcutaneous, or oral administration
of 12 to 20mg/kgof c-Rel inhibitor compound IT-603 and IT-901.
To assess the level of IT-603 and IT-901 in blood, samples were
analyzed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS) as previously described (22, 23). Calibration curves
were determined for IT-603 to permit conversion of peak areas to
the drug amounts against external reference standards. The tan-
dem MS/MS detector (Model ABI/Sciex API 4000, Applied
Figure 1.
IT-901 is a more potent c-Rel inhibitor than IT-603 and has a superior pharmacokinetic profile. A, structure of IT-901. B–D, plasma samples were analyzed at 30
minutes, 1, 2, 4, 6, and 16 hours after intraperitoneal administration of c-Rel inhibitor compounds IT-603 and IT-901. To assess the levels of IT-603 and
IT-901 in blood, samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS; for more details, see Materials and Methods).
B, pharmacokinetics of IT-901 utilizing different vehicles are shown. C, serum half-life (T1/2) and maximum concentration (Cmax) of IT-603 and IT-901 with different
vehicles are presented. D, pharmacokinetics of IT-901with GDM-12with different types of administrations are shown. i.p., intraperitoneal injection; s.c., subcutaneous
injection; p.o., per oral. E and F, wild-type C57BL/6 mouse splenocytes were treated with six different concentrations of IT-901 for 1 hour and analyzed
after anti-CD3/CD28 stimulation for 5 hours. E, levels of IL2 evaluated by ELISA in the culture supernatant are shown. F, representative flow-cytometric analysis of
intracellular c-Rel and IL2 are shown. Data are representative of more than three experiments. G and H, viability of the T cells after 24-hour incubation with
different concentrations of IT-603, IT-901, or empty vehicle. Percentages of live/dead cells and Annexin-V–positive proapoptotic cells are shown. Values
represent mean  SEM (n ¼ 5, technical replicates).  , P < 0.001 comparing IT-901 to empty vehicle. Data are representative of more than three experiments.
I and J, BALB/C-Tg(NFkB-RE-luc)-Xen mice were used for in vitro and in vivo analyses of c-Rel inhibitor compounds' effects on NFkB signaling. A total
of 1  106 splenocytes from NFkB-RE-luc mice were prepared in vitro with 1 mg/mL of LPS on a 96-well plate. Cells were treated with different concentrations
of IT-901, IT-603, or empty vehicle (control) for 24 hours and bioluminescent intensity was analyzed. I, pseudocolor images superimposed on conventional
photographs are shown. J, the bioluminescent signal intensity is shown. Data are representative of three independent experiments (I and J). Values represent
mean  SEM (n ¼ 3, technical replicates).  , P < 0.05;  , P < 0.01. K, in vivo treatment schedule of NFkB-RE-luc mice. L, the whole-body activation of NF-kB
signal was monitored using in vivo bioluminescence imaging (BLI). Pseudocolor images superimposed on conventional photographs are shown. Data are
representative of two independent experiments (K and L). Values represent mean  SEM (n ¼ 5);  , P < 0.05.
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Biosystem) permitted verification of peak identity as well as a
quantitative assessment of the compounds in the samples.
Xenograft model of EBV-induced B-cell lymphoma
Male NSG mice received 5  106 EBV-transformed B lympho-
blastoid cells that were transduced to express firefly luciferase via
subcutaneous injection on the back left side above the hind leg.
On day 8 after tumor challenge, animals were assigned to the
different groups and treatment with IT-901, vehicle, and/or EBV-
specific human T cells was initiated. A total of 2,000 units of
human IL2 were administered i.p. to all animals three times per
week starting on day 8 after tumor challenge. Tumor progression
was monitored by in vivo BLI and by caliper measurement.
Animals were sacrificed when tumors became ulcerated.
Statistical analysis
Data are presented as mean  SEM. Survival curves were
analyzed with the Mantel–Cox log-rank test. For longitudinal in
vivo studies measuring tumor volume, mice were randomly
assigned to the treatment groups and the area under the curve
(AUC) was used to summarize the trajectory of the measured
value of each mouse under study. Not all the mice were followed
for the full length of the study. The primary reason for censoring
was death or sacrifice, and ignoring this type of informative
censoring may result in a biased treatment comparison. To elim-
inate this bias, a test statistic was used that is formed based on the
information up to the minimum follow-up time for each cross
treatment mouse pair. By eliminating the uneven censorship
between mouse pairs in different groups, a test statistic can be
constructed that has mean zero when the growth rates in the two
groups are equal. The statistic is based on the average difference in
the censored AUC curves between treatment groups. P valueswere
generated fromapermutation test, using theAUCand log rank test
statistics. The application of the permutation procedure was due
to the "small" number of animals in these studies. For nonsurvival
pointwise analyses, unpaired t test was used for comparisons
between two experimental groups, or nonparametric Mann–
Whitney U test was used for non-Gaussian distributions, and
ANOVA was used for comparisons of more than two groups. A P
value of less than 0.05 was considered statistically significant.
Results
The c-Rel inhibitor IT-901 is a promising small molecule for
drug development
We previously introduced the thiohydantoin IT-603 as a small-
molecule c-Rel inhibitor, indicating that this intranuclear target is
indeed druggable (9). After additional testing and structure activ-
ity relationship analysis we identified the naphthalenethiobarbi-
turate IT-901 (Fig. 1A) as a second chemical lead. Electrophoretic
mobility shift assay (EMSA) and NF-kB DNA-binding ELISA
revealed that IT-901 efficiently inhibits DNA binding of c-Rel
(Supplementary Fig. S1A and S1B). The estimated half maximal
inhibitory concentration (IC50) regarding global NF-kB activity
was about six times lower for IT-901 (3 mmol/L) compared with
IT-603 (18.8 mmol/L), and compared with several reference drugs
NF-kB inhibition by IT-901 was only outperformed by the pro-
teasome inhibitor bortezomib (Supplementary Fig. S2).
Both IT-603 and IT-901 are hydrophobic but can easily be
dissolved in DMSO. We previously reported that IT-603/DMSO
was much less toxic than IT-901/DMSO when incubating T cells
for 24 hours and we therefore initially used IT-603/DMSO treat-
ment as our standard protocol for chemical induction of c-Rel
Figure 2.
c-Rel inhibitor administration is an effective treatment of acuteGVHDwithout impairing antitumor activity. A, lethally irradiated BALB/c recipientswere transplanted
with C57BL/6 TCD BM cells with 0.5  106 C57BL/6 wild-type T cells. c-Rel inhibitor compound IT-603, IT-901, or control vehicle solution was administered
i.p. from day 8 (24 mg/kg, every other day for 2 weeks). Survival curve is shown.  , P < 0.001 comparing recipients treated with IT-901 versus vehicle.
Data are representative of two independent experiments (n ¼ 10). B and C, lethally irradiated BALB/c recipients were transplanted with C57BL/6 TCD BM
cells with 0.5  106 C57BL/6 wild-type T cells. IT-901 or control vehicle solution was administered i.p. from day 8 (24 mg/kg, every other day for 2 weeks).
On day 0, HSCT recipients were challenged with 0.25 106 luciferase-expressing A20-TGL B-cell lymphoma cells. Survival curve is shown (B).  , P < 0.05 comparing
recipients treated with IT-901 versus vehicle. Data are representative of two independent experiments (n ¼ 3–10). The whole-body distribution of tumor
cells was monitored using in vivo BLI. For four time points, pseudocolor images superimposed on conventional photographs are shown (C). D, lethally
irradiated BALB/c recipients were transplanted with C57BL/6 TCD BM cells with 0.5  106 C57BL/6 wild-type T cells. IT-901 or control vehicle solution was
administered i.p. from day 8 (24 mg/kg, every other day for 2 weeks). Spleen and thymus were analyzed on day 21 after HSCT. Values represent mean  SEM
(n ¼ 5). Data are representative of two independent experiments. , P < 0.05;  , P < 0.01; NS, not significant.
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deficiency in vitro (9). In order to establish protocols for systemic
administration of a c-Rel inhibitor drug in preclinical models, we
formulated IT-603 and IT-901 with the FDA-approved nonionic
surfactant Cremophor as the vehicle for PK studies.We found that
intraperitoneally (i.p.) injected IT-901 had a superior PK profile
compared with IT-603 (Supplementary Fig. S3). Utilizing the
PEGylated synthetic lipid 1,2-dimyristoyl-rac-glycerol-3-dode-
caethylene glycol (GDM-12; ref. 24) for compound formulation
we further improved the PK profile of IT-901 (Fig. 1B) by increas-
ing the half-life (T1/2) and peak-concentration (Cmax; Fig. 1C). Of
note, both oral (p.o.) and especially subcutaneous (s.c.) admin-
istration of IT-901 resulted inmuch lower serum levels compared
with i.p. administration (Fig. 1D).
We next compared the in vitro efficacy of IT-901/GDM-12
versus IT-603/GDM-12 in a T-cell–based assay (please note that
the IC50 identified in these experiments will be different from the
ones obtained by experiments utilizing DMSO as vehicle and/or
biochemical instead of cell-based assays). IL2 is a well-known
c-Rel target gene in activated T cells (2, 3, 9). We therefore used
both flow cytometry and ELISA to measure IL2 expression in
activated T cells to assess the efficacy of our c-Rel inhibitor com-
pounds dissolved in 3% GDM-12. As expected, we found that IT-
901 was again more potent than IT-603 (Fig. 1E and Supplemen-
tary Fig. S3). The IC50 of IT-901/GDM-12 was 2.9 mmol/L for
c-Rel, whereas IL2 secretion was successfully blocked at 5 mmol/L
(Fig. 1F). Importantly, in contrast with our previous observations
with DMSO as the vehicle, cell viability was not compromised
following 24 hours of incubation in the presence of IT-901/GDM-
12 at concentrations up to 10 mmol/L (Fig. 1G and H). However,
we noticed that concentrations above 10 mmol/L become increas-
ingly toxic and may lead to apoptosis of healthy cells.
In order to confirm the inhibitory effect of IT-901 on NF-kB
pathway activity both in vitro and in vivo, we utilized BALB/c-Tg
(NFkB-RE-luc)-Xen mice that carry a transgene containing NF-
kB–responsive elements and modified firefly luciferase cDNA
(25). Incubation of LPS-stimulated splenocytes from NFkB-RE-
luc mice in the presence or absence of c-Rel inhibitors demon-
strated inhibition of NF-kB activity by both IT-603 and IT-901,
again showing stronger inhibition by IT-901 (Fig. 1I and J).
Moreover, NFkB-RE-lucmice injected with LPS following a single
dose of IT-901 (Fig. 1K) showed significant inhibition of NF-kB
activity seven hours after treatment (Fig. 1L), confirming that IT-
901 inhibits c-Rel/NF-kB both in vitro and in vivo.
c-Rel inhibitor administration is an effective treatment of acute
GVHD without impairing antitumor activity
Next, we performed toxicology studies demonstrating that
healthy C57BL/6 mice treated with i.p. or high-dose p.o.
Figure 3.
IT-901 inhibits tumor growth in a xenograftmodel of human EBV-induced B-cell lymphoma. A, human EBV-BLCL and control humanCD19þPBMCwere cultured for 3
days in the presence of serial dilutions of IT-901. Relative cell growth was measured by MTS Cell Proliferation Assay. Mean  SEM of technical replicates are
presented. B–D, in vivo efficacy of IT-901 in a xenograft model of EBV-induced B-cell lymphoma. B, 5  106 EBV-BLCL were administered subcutaneously
above the left hind leg of NSG mice. On day 8 after tumor challenge, treatment with IT-901 (20 mg/kg, i.p. daily) versus vehicle or no treatment was initiated.
Tumor volume was measured manually with a caliper at the indicated time points. Mean  SEM are presented (n ¼ 5). One of two independent experiments is
presented.  , P < 0.01. C, H&E staining of whole tumors harvested at day 25 after start of treatment. Left, representative images of tumors harvested from
the three groups. Purple areas represent viable lymphoma cells, pink areas represent necrosis. Right, area of necrosis of whole tumors was determined based
on H&E staining. Mean  SEM are presented.  , P < 0.05. D, 5  106 EBV-BLCL were administered subcutaneously above the left leg of NSG mice. All animals
received three infusions of 10 106 EBV-specific human cytotoxic T lymphocytes inweekly intervals starting day 8 after tumor challenge. In addition, treatment with
IT-901 (20 mg/kg, i.p. daily) versus vehicle or no treatment was initiated on day 8 after tumor challenge. Tumor volume was measured manually with a caliper
at the indicated time points. Mean  SEM are presented (n ¼ 5). One of two independent experiments is presented.
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(150mg/kg) IT-901 for 14 days had no clinical symptoms and no
changes in their numbers of splenocytes, thymocytes, and T-cell
subsets (Supplementary Fig. S5 and Supplementary Table S1).
However, when administering IT-901 daily i.p. for more than 2
weeks we observed diarrhea, ruffled fur, and up to 10% weight
loss.
On the basis of previous work by us and others (9, 26), we
hypothesized that systemically administered IT-901 may be
efficacious in the treatment of acute GVHD, an immunologic
disorder that critically depends on NF-kB and specifically c-Rel
activity for T-cell activation by alloantigens (9). We chose a
treatment dose of 24 mg/kg based on our PK studies and dose-
response in vitro data, with the goal of reaching IT-901 serum
levels within the expected therapeutic range (0.5–1 mg/mL,
equivalent to 1.5–3 mmol/L). Initiation of i.p. IT-901 treatment
within one week after HSCT was poorly tolerated and therefore
not feasible. This phenomenon can likely be attributed to the
low level of stress tolerance of mice in the immediate time
period post lethal irradiation. Moreover, NF-kB inhibition in
the setting of acute exposure to high-dose irradiation may
sensitize tissues such as the intestinal epithelium to radio-
toxicity (27). When initiating treatment after day 7 following
HSCT, gut toxicity was still dose limiting, precluding daily
inhibitor administrations (not shown). However, administra-
tion every other day starting on day 8 after HSCT was well
tolerated and effectively improved the severity of lethal acute
GVHD (Fig. 2A and Supplementary Fig. S6). Of note, IT-901
was again more efficacious than IT-603, and the therapeutic
benefit was sustained even after cessation of c-Rel inhibitor
treatment. Moreover, IT-901 treatment did not abolish the
antitumor activity of donor T cells (Fig. 2B and C), reinforcing
our previous observation that inhibition of c-Rel activity
improves GVHD without impairing antitumor responses (9).
Consistent with our previous results with IT-603, we demon-
strated an increase of the percentage of donor regulatory T cells
following IT-901 treatment during GVHD, but otherwise no
differential effect on the immune status of the recipients (Fig.
2D and Supplementary Fig. S7).
Figure 4.
IT-901 inhibits growth of human DLBCL and modulates the cytokine profile of activated B-cell lymphoma cells. A, SU-DHL8 and TMD8 cells were cultured in the
presence of IT-901 (3 mmol/L) or control vehicle solution for 24 hours. Nuclear translocation of four NF-kB subunits (p65, p52, p50, and c-Rel) was analyzed
by flow cytometry. Values represent mean  SEM (n ¼ 2, technical replicates). B and C, human DLBCL cell lines were treated with IT-901 (4 mmol/L) or control
vehicle for 48 hours. Annexin-V–positive proapoptotic cells are shown (B). Viability of the tumor cells after 48-hour incubation is shown in C (normalized values to
vehicle treatment). Values represent mean  SEM (n ¼ 4, technical replicates). Data are representative of two independent experiments. D, human DLBCL
cell lines were treated for 3 days with serial dilutions of IT-901. Relative cell growth was measured by MTS Cell Proliferation Assay. Data are representative
of three independent experiments. E, TMD8 and SU-DHL8 cells were cultured in the presence of IT-901 (1–5 mmol/L) or control vehicle solution for 24 hours and
viability as well as Ki-67 expression was analyzed by flow cytometry. Percentages of Ki-67þ proliferating viable cells are shown. Data are representative
of two independent experiments. F, TMD8 tumor cells were cultured in the presence of IT-901 (3 mmol/L) or control vehicle solution for 24 hours. Cytokine levels
of the supernatant are shown (Multiplex ELISA). Mean values and SEM are presented (samples were analyzed in triplicates).  , P < 0.05. Dotted line indicates
theminimum detection limit of the assay. G, TMD8 tumor cells were cultured in the presence of IT-901 (3 mmol/L) and anti-TNFa antibody (ADALIMUMAB; ADA) for
48 hours. Relative cell growth was measured by MTS Cell Proliferation Assay. Values represent mean  SEM (n ¼ 4, technical replicates).  , P < 0.05. Data are
representative of two independent experiments.
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Figure 5.
Antilymphomaefficacyof IT-901 ismediated by oxidative stress. A andB, Ly19 and SU-DHL8 tumor cellswere treatedwith IT-901 (4mmol/L), or control vehicle for 24
hours. Heme oxygenase 1 (HMOX1) gene expression level by qPCR and protein level by ELISA are shown (A and B), respectively. Dotted line indicates the
minimumdetection limit of the assay.N.D, not detected. C, SU-DHL8 tumor cellswere treatedwith IT-901 (4mmol/L) for 24 hours and stainedwith carboxy-H2DCFDA
for microscopic detection of ROS. Representative confocal microscope images are shown (blue; DNA, red; Mitochondria, green; ROS; for more experimental
details, see Materials and Methods). Data are representative of two independent experiments. D and E, Ly19 cells were treated with IT-901 at 4 mmol/L
or control vehicle for 24 hours and mitochondrial respiration was analyzed with extracellular flux assays (see Materials and Methods for more experimental details).
Proton leak (¼ non-ATP linked respiration; D) and ATP-linked OCR are presented (E).  , P < 0.0001. F, Ly19, SU-DHL8, and TMD8 cells were treated in vitro
with IT-901 (4 mmol/L) or control solution for 24 hours. Cells were analyzed for total and oxidized glutathione by HT Glutathione Assay Kit as described in
Materials and Methods and the levels of reduced glutathione are presented. Values represent mean  SEM. P ¼ 0.015 when mean levels of reduced GSH
from each cell line (n ¼ 3) were compared with control. G, Ly19 and TMD8 tumor cells were treated with IT-901 (4 mmol/L) or control vehicle solution for 24 hours
with or without N-Acetyl-L-cysteine (NAC). Relative cell growth was measured by MTS Cell Proliferation Assay. Values represent mean  SEM (n ¼ 4,
technical replicates).  , P < 0.01. H, Ly19 and TMD8 tumor cells were treated with IT-901 (4 mmol/L) or control vehicle solution for 24 hours to analyze reactive
oxygen species (ROS). Wild-type C57BL/6 mouse splenocytes were also cultured in the same condition. ROS levels were analyzed by utilizing a fluorogenic
marker (carboxy-H2DCFDA) and normalized to the level of vehicle-treated cells. Values represent mean  SEM (n ¼ 4, technical replicates).  , P < 0.05;
 ,P <0.01. I, Ly19, SU-DHL8, and TMD8 tumor cellswere treatedwith IT-901 (4 mmol/L), or control vehicle for 24 hours. Levels of hydrogen peroxide, nitric oxide, and
superoxide after the treatment are shown (normalized values to vehicle treatment, dotted line indicates the level of control vehicle-treated group). Values
represent mean  SEM (n ¼ 3, technical replicates). Data are representative of two independent experiments. J, Ly19, SU-DHL8, and TMD8 cells were treated
in vitro with IT-901 (4 mmol/L) or control solution for 24 hours. Total iNOS levels are shown in as determined by cell-based human total iNOS immunoassay
kit (ELISA). P ¼ 0.023 when mean iNOS activities from each cell line (n ¼ 3) were compared with control. (Continued on the following page.)
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IT-901 inhibits tumor growth in a xenograft model of human
EBV-induced B-cell lymphoma
Rel/NF-kB proteins can act as oncogenic transcription factors
by contributing to tumor growth, survival, drug resistance, and
metastasis (1, 7). The combination of c-Rel inhibition and T-
cell therapy may therefore not only be advantageous in that this
immunomodulatory approach allows for the separation of
GVHD from GVL activity, but inhibition of c-Rel activity may
also display a direct antineoplastic effect. Recent genetic evi-
dence has established a role for NF-kB signaling in lymphoid
malignancies (28). To provide a rationale for clinical applica-
tion of our c-Rel inhibitor technology to lymphoid malignan-
cies, we analyzed c-Rel gene expression in various human
cancer cells. We found particularly high expression of the c-
Rel gene in human EBV-transformed B cells and diffuse large B-
cell lymphoma (DLBCL) cell lines (Supplementary Fig. S8A and
S8B). Moreover, we demonstrated nuclear translocation of c-
Rel (indicating constitutive c-Rel activity) in a wide range of
human primary lymphoma cells, especially in DLBCL and EBV-
transformed B cells (Supplementary Fig. S8C). Treatment of a
human EBV-B cell lymphoblastoid cell line (BLCL) with IT-901
in vitro induced inhibition of cell growth, whereas the numbers
of normal B lymphocytes were not altered by IT-901 treatment
(Fig. 3A). We next analyzed the in vivo efficacy of IT-901 in a
human EBV-induced B-cell lymphoma xenograft model and
found that treatment with IT-901 significantly inhibited tumor
growth (Fig. 3B). In addition, the area of necrosis was signif-
icantly larger in tumors harvested from mice receiving IT-901
(Fig. 3C). EBV-associated lymphoma is a rare but life-threat-
ening complication occurring mostly in severely immunocom-
promised patients in the setting of allogeneic HSCT (29).
Immunotherapy with EBV-specific cytotoxic T lymphocytes has
been shown to be an effective treatment option for this disease
(30). Importantly, IT-901 treatment did not compromise the
efficacy of T-cell therapy in this model (Fig. 3D and Supple-
mentary Fig. S9), underscoring that in contrast with alloimmu-
nity, protective antilymphoma immunity mediated by antigen-
specific T cells is not impaired by IT-901 treatment (see ref. 9 for
additional mechanistic information).
IT-901 inhibits growth of human DLBCL cells
On the basis of gene expression profiling, it is well known
that there are two molecularly distinct forms of DLBCL: acti-
vated B-like (ABC) and germinal center B-like (GCB) DLBCL
(31). We therefore analyzed nuclear translocation of c-Rel as
well as of three additional NF-kB family members (p50, p52,
and p65) in six representative DLBCL cell lines including ABC
(HBL1, TMD8, U2932) and GCB (Ly19, SU-DHL4, SU-DHL8)
cell lines and found that c-Rel and overall NF-kB activity was
highest in ABC DLBCL cells (Supplementary Fig. S10). Impor-
tantly, IT-901 treatment strongly suppressed constitutive c-Rel
activity of DLBCL cells but had a weaker effect on p50 and p52
activity and only mildly affected p65 activity (Fig. 4A). The
"cross-reactivity" of IT-901 regarding Rel proteins other than c-
Rel does not come as a surprise given that this family of
proteins is structurally related (32). Although IT-901 treatment
decreased cell viability in a dose-dependent fashion, at least 60
percent of cells were still viable after 48 hours of IT-901
treatment (4 mmol/L) in all tested cell lines except HBL1 (Fig.
4B and C).
We next investigated whether IT-901 treatment affected
growth of DLBCL cells in vitro. To our surprise we found that
IT-901 inhibited cell growth of both ABC and GCB cell lines
with the IC50 values between 3mmol/L to 4mmol/L (Fig. 4D
and Supplementary Fig. S11). In addition, IT-901 resulted in
decreased proliferation of viable ABC and GCB DLBCL cells
(determined by Ki-67 expression; Fig. 4E). This suggests that
the decreased lymphoma cell numbers in response to IT-901
treatment were not just the result of cell death but also due to
slower cell growth.
Inhibition of c-Rel identifies TNFa as a possible therapeutic
target in ABC DLBCL cells
NF-kB plays an important role in the initiation and promotion
of cancer by fostering an inflammatory milieu in which various
cytokines aid and abet malignant transformation (33). To exam-
ine whether IT-901 alters cytokine production by DLBCL cells, we
analyzed cytokine levels in the supernatant after in vitro incuba-
tion with IT-901. As anticipated, cytokine levels were hardly
detectable in GCB DLBCL cells (not shown), in contrast with
ABC DLBCL cells, where TMD8 showed marked production of
various cytokines. IT-901 treatment resulted in decreases of most
cytokine levels in TMD8 cells, with the notable exceptions of IL8,
TNFa, and TNFb (Fig. 4F). Interestingly, TMD8 was the only
DLBCL cell line that did not show inhibited growthwhen cultured
with IT-901 at a concentration of 3 mmol/L (Fig. 4D), suggesting
that in TMD8 cells cytokines such as IL8 and TNFa may be
increased as a mechanism to overcome c-Rel inhibition by com-
pensatory upregulation of NF-kB–dependent survival pathways.
Indeed, in vitro treatment of TMD8 cells with a TNFa neutralizing
antibody inhibited cell growth, and this effectwas enhancedwhen
combining TNFa blockade with IT-901 treatment (Fig. 4G),
suggesting that the TNFa pathway may be a therapeutically
exploitable target in some B-cell lymphomas.
(Continued.) K, Ly19 tumor cells were treated with pyocyanin (PYO) to generate high levels of oxidative stress in the presence of vehicle versus IT-901 or
PS-1145 (at 4 mmol/L, open bars), or in the presence of mock versus c-Rel-specific shRNA (#2131 and #2205, gray bars) for 24 hours, followed by analysis
of HMOX1 induction. HMOX1 protein level by ELISA is shown. Dotted line indicates the minimum detection limit of the assay. Values represent mean  SEM
(n ¼ 5, technical replicates).  , P < 0.05; , P < 0.001. See Materials and Methods for more experimental details. L, Ly19 cells were treated for 3 days with
PS-1145 (4 mmol/L), pyocyanin (350 mmol/L), or PS-1145 (4 mmol/L) þ pyocyanin (350 mmol/L). Relative cell growth was measured by MTS assay. Combined
data from two independent experiments are presented. M, the proposed effects of IT-901 on oxidative stress induction and the oxidative stress response in
lymphoma cells. Left, upon ROS induction, HMOX1 is upregulated through NF-kB activation and this serves as an antioxidant response. At the same time,
the level of iNOS is expected to be decreased as iNOS production is negatively regulated by the NF-kB pathway. Impacts of ROS induction are indicated by blue
arrows. Right, in the setting of IT-901 treatment, three major responses are observed: (i) buildup of ROS as a result of GSH depletion; (ii) suppression of HMOX1
due to decreased NF-kB/c-Rel activity, which weakens the oxidative stress response; and (iii) induction of iNOS by inhibiting its negative regulator
NF-kB/c-Rel, resulting in production of nitric oxide. Increased production of ROS/RNS contributes to the production of peroxynitrite, which exacerbates
ROS-mediated DNA damage and cell death. Impacts of IT-901 are indicated by red arrows and cross marks. Changes that affect ROS removal are shown in green.
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IT-901 mediates anti-lymphoma activity by selective induction
of oxidative stress in lymphoma cells
The nonselective inhibitory effect of IT-901 on growth of
both ABC and GCB DLBCL cells led us to conclude that an NF-
kB–independent mechanism contributed to the antilymphoma
activity of IT-901. Various interactions between the oxidative
stress response and NF-kB signaling have been proposed (34).
Oxidative stress is an important element of anticancer thera-
pies, although it has been implicated in tumorigenesis as well
(35, 36). Heme oxygenase-1 (HMOX1) is an oxidative stress
response gene (37) whose expression is regulated by NF-kB. We
found that HMOX1 gene expression was highly upregulated in
DLBCL cells treated with IT-901 for 6 hours (Fig. 5A). Further-
more, we detected significantly increased HMOX1 protein
levels in Ly19 and SU-DHL8 cells treated with IT-901 for 24
hours (Fig. 5B) suggesting that HMOX1 expression was
induced, which is a hallmark of oxidative stress. Oxidative
stress is mediated by ROS that are created by a variety of
cellular processes including electron leakage from mitochon-
drial respiratory complexes (38). We therefore next checked for
the presence of ROS in cells treated with IT-901 and found that,
as expected, ROS production was largely localized within
mitochondria (Fig. 5C and data not shown). Interestingly,
analysis of mitochondrial respiration in Ly19 cells that were
incubated with IT-901 for 24 hours revealed increased mito-
chondrial proton leak (equivalent with non-ATP linked oxygen
consumption; Fig. 5D). It is a well-known phenomenon that
there is a positive feedback loop between ROS and proton leak,
reflecting cellular adaption to oxidative stress (39). Consistent
with increased proton leak, ATP-linked mitochondrial respira-
tion was decreased in IT-901–treated cells, indicating mito-
chondrial dysfunction (Fig. 5E).
Oxidative stress is the result of an imbalance between gener-
ation and elimination of ROS. One of the major ROS-scavenging
systems is glutathione (GSH; ref. 40). Given that the IT-901
molecule has redox properties, we hypothesized that IT-901 may
alter the GSH homeostasis in affected cells. Indeed, we found that
the levels of reduced GSH of DLBCL cells were significantly
decreased following IT-901 treatment (Fig. 5F), suggesting that
depletion of the reducedGSHpool by IT-901 initiates the increase
in ROS levels. Replenishing the GSH pool of DLBCL cells by the
addition of the antioxidant N-Acetyl-L-cysteine completely
reversed the inhibitory effect of IT-901 on DLBCL growth, indi-
cating that induction of oxidative stress by GSH modulation was
indeed themain factor contributing to the antilymphoma activity
of IT-901 (Fig. 5G). IT-901 induced production of high levels of
ROS inbothABCandGCBDLBCL cells (Fig. 5H).Of note, normal
leukocytes generated noROS in response to treatmentwith IT-901
(Fig. 5HandSupplementary Table S2), suggesting that lymphoma
cells are particularly sensitive to inductionof oxidative stress by IT-
901. Analysis of several reactive oxygen and nitrogen species
revealed that superoxide and nitric oxide (NO) but not hydrogen
peroxide levels were increased in lymphoma cells treated with IT-
901 (Fig. 5I). Of note, superoxide and NO react spontaneously to
form the highly toxic oxidant peroxynitrite, which is known to
cause lipid, protein, and DNA damage, and therefore cell death
(34). NO can be produced by various cell types that are capable of
expressing inducible NO synthase (iNOS). iNOS is an NF-kB
target gene and it has been previously shown that NF-kB activa-
tion in Burkitt lymphoma cells was associated with inhibition of
NO production (41). Consistent with this report we found that
treatment with theNF-kB inhibitor IT-901 increases iNOS activity
in B-cell lymphoma cells (Fig. 5J).
Finally, we sought to investigate the impact of c-Rel inhibition
on the oxidative stress response. We hypothesized that IT-901
would not only induce oxidative stress, but also suppress antiox-
idant genes via inhibition of NF-kB target genes involved in the
oxidative stress response such as HMOX1. We treated Ly19 cells
with thepro-oxidant pyocyanin to generatehigh levelsof oxidative
stress, followed by analysis of HMOX1 (using HMOX1 as a
surrogate marker of the NF-kB–dependent oxidative stress
response) in the presence of vehicle versus NF-kB inhibitors
(IT-901 or the IKK inhibitor PS-1145; ref. 42; Fig. 5K, open bars),
or in the presence of mock versus c-Rel–specific shRNA (Fig. 5K,
gray bars). We found that c-Rel/NF-kB inhibition with PS-1145,
IT-901, or shRNA indeedmodulated the oxidative stress response,
exemplified by reduced HMOX1 induction in the presence of
pyocyanin. We therefore next investigated whether NF-kB inhibi-
tion on the setting of oxidative stress had the potential to sensitize
lymphoma cells to oxidative stress-mediated cell damage. We
cultured Ly19 cells in the presence of oxidative stress without
NF-kB inhibition (pyocyanin alone), in the presence of NF-kB
inhibition in the absence of oxidative stress (PS-1145 alone), or in
the presence of oxidative stress in the setting of NF-kB inhibition
(pyocyanin þ PS-1145, which is equivalent to the proposed dual
mechanism of IT-901; Fig. 5L). We found that NF-kB inhibition
alone had no effect on Ly19 growth, induction of oxidative stress
strongly inhibited lymphoma cell growth, and combining oxida-
tive stress and NF-kB inhibition had additive antilymphoma
effects. The proposed effects of IT-901 on oxidative stress induc-
tion and the oxidative stress response are summarized in Fig. 5M.
Discussion
Although the NF-kB pathway is involved in a multitude of
physiologic and pathophysiological processes affecting both
hematopoietic and nonhematopoietic cells, healthy cellular
steady state is not associated with NF-kB activity. A truly NF-
kB–specific drug would therefore not be expected to disturb
normal cell function. Clinical strategies resulting in suppression
of NF-kB activity include proteasome inhibitors (43), Bruton's
tyronsine kinase inhibitors (44, 45), thalidomide and its analogs
(46, 47), amongst others. None of these approaches is strictly NF-
kB–specific, enhancing the potential of these agents for both
therapeutic and adverse effects. Increasing NF-kB specificity of
a given drug would be expected to improve the safety profile,
possibly at the expense of reducing efficacy for some indications
(such as cancer). Here, we show that small-molecule–mediated
inhibition of the NF-kB pathway at the transcription factor level
can efficiently be accomplished in vivo and is associated with little
toxicity. Moreover, we are able to demonstrate improved in vivo
efficacy of amultidose c-Rel inhibitor treatment regimen for acute
lethal GVHD. The importance of this finding should not be
underestimated given the issues with proteasome and IkB kinase
(IKK) inhibitors in exacerbating acute GVHD (48, 49). Further-
more, our data confirm our previous findings (9) that both
antitumor and anti-viral activity of T cells is not compromised
by c-Rel inhibitor treatment, adding to the favorable safety profile.
c-Rel is well known for its role as an oncogenic transcription
factor, contributing to constitutiveNF-kB activity in awide range of
cancers (7), most notably in lymphoid malignancies (50–52). We
show that c-Rel is particularly overexpressed and constitutively
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active in DLBCL cells and EBV-transformed B lymphoblasts. As
expected, in vitro c-Rel inhibitor treatment modulated the cytokine
profile of DLBCL cells with high NF-kB activity (ABC but not GCB
DLBCL cells), consistent with a previous study describing differ-
ential effects of IKK inhibitor treatment onABCversusGCBDLBCL
cells (42). In contrast with this, IT-901 had an inhibitory effect on
cell growth of both of these distinct DLBCL types, suggesting that
NF-kB inhibition was not the main factor affecting lymphoma cell
behavior in the presence of the small molecule. We identified an
additional mechanism of action of IT-901 that takes advantage of
the fact that ROS production is increased in cancer cells and that
modulation of the redox homeostasis has potential to be thera-
peutically exploited as a method to selectively cause toxicity to
cancer cells while sparing healthy tissues (40). Importantly, there is
a threshold range of ROS-mediated effects on cellular function.
ROS levelsbelow the critical thresholdmayactuallybebeneficialby
stimulating pro-survival signaling pathways, whereas levels exceed-
ing the threshold become harmful and result in cell death (40, 53).
We found that culturing cells in the presence of IT-901 depletes
their reduced GSH pool, which impairs ROS elimination and
results in superoxide accumulation in B-cell lymphoma cells (but
not in normal leukocytes where basal superoxide generation is
negligible; ref. 54). IT-901–mediated NF-kB inhibition further
exacerbated oxidative stress in lymphoma cells by inducing iNOS
activity (thereby generating nitric oxide and enabling formation of
peroxynitrite) while inhibiting oxidative stress response elements
that are regulated by NF-kB (as illustrated by modulation of a
representativeoxidative stress response gene;HMOX1). Important-
ly, we were able to demonstrate additive antilymphoma effects of
combination treatment with a pro-oxidant in the presence of an
NF-kB inhibitor. IT-901 therefore represents a novel small mole-
cule acting as a direct c-Rel/NF-kB inhibitor with additional anti-
neoplastic activity secondary to selective induction of oxidative
stress in lymphoma cells (the latter mechanism being exacerbated
by NF-kB inhibition).
Interestingly, exposing lymphoma cells to IT-901 in the
presence of an antioxidant reversed the anti-lymphoma effect
of the small molecule even in ABC DLBCL cell lines depending
on constitutive NF-kB activity for their survival. These observa-
tions reinforce the notion that for the treatment of malignant
diseases, small-molecule–mediated NF-kB inhibition at the
transcription factor level may not be sufficient to mediate
strong anti-neoplastic activity in a single-agent treatment reg-
imen. However, consistent with NF-kB inhibition, IT-901 mod-
ulated the cytokine profile of ABC DLBCL cells, leading us to
identify TNFa as a potential therapeutic target in activated B-
cell lymphomas. Combination of c-Rel/NF-kB inhibition with
additional cytostatic or targeted approaches has significant
potential for the development of innovative minimally toxic
cancer treatment protocols. Examples for rational combination
strategies include NF-kB inhibition þ inhibition of upstream
targets such as TNFa (Fig. 4G), tyrosine kinases, VEGF, or c-Rel
inhibition þ checkpoint blockade such as cytotoxic T lympho-
cyte antigen 4 (CTLA4) inhibition (where c-Rel inhibition
could mitigate adverse effects related to increased autoreactivity
in the setting of reduced peripheral tolerance).
Taken together, we introduce the novel small-molecule IT-901,
a compound with unique properties that may benefit allogeneic
transplantation as well as cancers therapy. Because of its strong c-
Rel/NF-kB inhibitory potency combined with its capacity to
induce high levels of oxidative stress specifically in lymphoma
cells, the overall efficacy of IT-901 is far superior to our previous
drug candidate IT-603. IT-901 has significant potential as anti-
neoplastic agent for the treatment of hematologic malignancies,
especially in the setting of allogeneic HSCTwhere c-Rel inhibition
has the added benefit of ameliorating GVHD. Moreover, our
findings indicate that IT-901 is not only efficacious and well
tolerated but our PK and toxicology data suggest that this mol-
ecule is a promising candidate for clinical drug development.
Issues that will need to be addressed before application to human
subjects include additional investigational new drug–directed
toxicology studies, as well as the development of an optimized
clinically acceptable formulation.We expect to be able to launch a
first-in-man clinical trial within the next 3 years.
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